Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
AssigneeSanofi
InventorsDavide Radzik, Martin Van Eickels, Nacéra Hamdani, Christophe Gaudin
Life of this patent
Estimating the term…
Abstract
Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
Claims24
A method of decreasing a risk of cardiovascular hospitalization in a patient, said method comprising administering to said patient an effective amount of dronedarone or a pharmaceutically acceptable salt thereof, twice a day with a morning and an evening meal, wherein said patient does not have severe heart failure, (i) wherein severe heart failure is indicated by:
- a) NYHA Class IV heart failure or b) hospitalization for heart failure within the last month;
- and (ii) wherein said patient has a history of, or current, paroxysmal or persistent non-permanent atrial fibrillation or flutter;
- and (iii) wherein the patient has at least one cardiovascular risk factor selected from the group consisting of:
- i. an age greater than or equal to 75;
- ii. hypertension;
- iii. diabetes;
- iv. a history of cerebral stroke or of systemic embolism;
- v. a left atrial diameter greater than or equal to 50 mm;
- and
- vi. a left ventricular ejection fraction less than 40%.
A method of treating a patient with a recent history of or current atrial fibrillation or flutter, said method comprising administrating to said patient a therapeutically effective amount of dronedarone, or a pharmaceutically acceptable salt thereof, twice a day with a morning and an evening meal, wherein said patient does not have severe heart failure, (i) wherein severe heart failure is indicated by:
- a) NYHA Class IV heart failure or b) hospitalization for heart failure within the last month, and (ii) wherein said atrial fibrillation or flutter is non-permanent and is paroxysmal or persistent;
- and (iii) wherein the patient has at least one cardiovascular risk factor selected from the group consisting of:
- i. an age greater than or equal to 75;
- ii. hypertension;
- iii. diabetes;
- iv. a history of cerebral stroke or of systemic embolism;
- v. a left atrial diameter greater than or equal to 50 mm;
- and
- vi. a left ventricular ejection fraction less than 40%.
A method of decreasing a risk of hospitalization for atrial fibrillation in a patient having a history of atrial fibrillation or atrial flutter, said method comprising administering dronedarone, or a pharmaceutically acceptable salt thereof, twice a day with a morning and an evening meal to a patient in need thereof, wherein said patient does not have severe heart failure, (i) wherein severe heart failure is indicated by:
- a) NYHA Class IV heart failure or b) hospitalization for heart failure within the last month, and (ii) wherein said atrial fibrillation or flutter is non-permanent and is paroxysmal or persistent;
- and (iii) wherein the patient has at least one cardiovascular risk factor selected from the group consisting of:
- i. an age greater than or equal to 75;
- ii. hypertension;
- iii. diabetes;
- iv. a history of cerebral stroke or of systemic embolism;
- v. a left atrial diameter greater than or equal to 50 mm;
- and
- vi. a left ventricular ejection fraction less than 40%.
Dependencies are inferred from the claim text.